Drug Trial Radar · NCT00349375
Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
Last checked: Nov 20, 2026Latest source record: Jul 8, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,040
Actual
Start
Nov 2005
Primary completion
Sep 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Solvay PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
Conditions
- Hyperlipidemia
Interventions
Fenofibrate/SimvastatinDrug
Combination of Fenofibrate 145mg and Simvastatin 20mg
Fenofibrate/SimvastatinDrug
Combination of Fenofibrate and Simvastatin 40 mg
SimvastatinDrug
Simvastatin 40 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline to 24 weeks of treatment in TriglyceridesTime frame: 12 weeks
- Percent change from baseline to 24 weeks of treatment in HDL-CTime frame: 12 weeks
- Percent change from baseline to 24 weeks of treatment in LDL-CTime frame: 12 weeks
Locations
110 sites in 8 countries. Site status is shown where the registry gives one.
Site 008
Brno, Czechia
Site 009
Brno, Czechia
Site 010
Brno, Czechia
Site 015
Hradisk, Czechia
Site 019
Karlovy Vary, Czechia
Site 014
Kladno, Czechia
Site 005
Nymburk, Czechia
Site 012
Olomouc, Czechia
Site 013
Olomouc, Czechia
Site 007
Pilsen, Czechia
Site 018
Pilsen, Czechia
Site 001
Prague, Czechia
Site 002
Prague, Czechia
Site 003
Prague, Czechia
Site 004
Prague, Czechia
Site 016
Příbram, Czechia
Site 017
Příbram, Czechia
Site 011
Slaný, Czechia
Site 006
Tábor, Czechia
Site 201
Copenhagen, Denmark
Site 205
Copenhagen, Denmark
Site 203
Hvidovre, Denmark
Site 302
Bouliac, France
Site 314
Briollay, France
Site 318
Corsept, France
Site 301
Dijon, France
Site 317
La Montagne, France
Site 321
Le Mesnil En Valee, France
Site 316
Loudon, France
Site 308
Mont-de-Marsan, France
Site 312
Mûrs-Erigné, France
Site 310
Nantes, France
Site 304
Niort, France
Site 319
Orvault, France
Site 306
Paris, France
Site 305
Pouilly-en-Auxois, France
Site 307
Rouen, France
Site 311
Rouen, France
Site 303
Saint-Justin, France
Site 315
Thouars, France
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.